Ophthalmic drug development has a stubborn problem: getting enough drug to the right place, safely, and consistently. Now, Formosa Pharmaceuticals, Inc. and the Singapore Eye Research Institute (SERI) are teaming up to tackle exactly that.
This isn’t just another research collaboration. It’s a platform + clinical expertise play.
These are areas where current treatments often fall short.
Conditions affecting the cornea and ocular surface are deceptively complex:
The result? Many therapies work in theory—but underperform in real-world use.
Formosa’s APNT platform is built on a simple but powerful principle: Make drug particles smaller—much smaller. This enables:
In short: more drug where it matters, less wasted.
Technology alone doesn’t fix clinical problems. That’s where SERI comes in. Led by Yu-Chi Liu, the collaboration is grounded in real disease biology. Her expertise includes:
This matters because formulation decisions will be guided by actual patient pathology, not just lab assumptions.
One of the most overused phrases in biotech is “translational research.” But here, it’s central to the strategy. The goal is clear: turn formulation innovation into clinically meaningful therapies. That means:
According to Formosa, initial work has already shown:
This is early—but it’s the kind of early signal that determines whether partnerships stall or scale.
If this collaboration delivers, expect:
Not incremental improvements, functional upgrades in how ophthalmic drugs work.
This move fits neatly into Formosa’s broader playbook:
It’s not about discovering new molecules. It’s about making existing ones work better.
Ophthalmology doesn’t lack drugs. It lacks effective delivery. By combining:
this collaboration targets a real bottleneck in eye care. Now the question is execution. Because in drug delivery, the science is only half the battle—the rest is proving it actually improves patient outcomes.